Companies: 10,795·Total market cap: $144.5T
Assembly Biosciences, Inc.

Assembly Biosciences, Inc.

ASMBNASDAQHealthcare● Active
$22.56
$-0.35(-1.51%)
Market Cap$358464382
P/E Ratio
52W High$39.71
52W Low$15.54

Assembly Biosciences, Inc. (ASMB) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

asmb · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 11 Wall Street analysts in the past 3 months

SellBuy

Buy

11 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
6
Hold
5
Sell
0
Strong Sell
0
Total: 11 · Buy rate: 54.5%

12-Month Price Target

High

$40.00

Consensus

$37.67

+67.0% upside

Low

$35.00

Median: $38 · Last Close: $22.56

The Assembly Biosciences, Inc. (ASMB) analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month ASMB price target is $37.67, representing +67.0% upside from the current price of $22.56.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $38 (67.0%)

Consensus Target

$37.67

67.0% upside

High Target

$40

77.3%

Low Target

$35

55.1%

Current Price

$22.56

as of today

Based on analyst price targets, the ASMB stock price prediction for the next 12 months ranges from $35 to $40. The consensus ASMB price forecast of $37.67 implies 67.0% upside from the current price of $22.56.

Short-Term Price Prediction

Bear

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$21.435.00%

1-day model range: $21.24–$21.62. Peak: $21.62 (-5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$29+30.3%
2028$34+52.0%
2029$37+66.0%
2030$39+74.3%
2031+79.2%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

7%0%93%
1Buy
0Neutral
13Sell
RSI (14)27.2Oversold
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · ASMB · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$23.73SELL
MA 10$25.71SELL
MA 20$27.20SELL
MA 50$28.02SELL
MA 100$28.05SELL
MA 200$28.98SELL
Current $ASMB · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$23.84SELL
EMA 10$25.06SELL
EMA 20$26.35SELL
EMA 50$27.60SELL
EMA 100$28.14SELL
EMA 200$27.03SELL
Current $ASMB · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Guggenheim2026-05-28
Maintains
BuyBuy
HC Wainwright & Co.2026-05-04
Maintains
BuyBuy
Guggenheim2026-04-06
Maintains
BuyBuy
HC Wainwright & Co.2026-03-26
Maintains
BuyBuy
HC Wainwright & Co.2025-12-22
Maintains
BuyBuy
Mizuho2025-11-20
Maintains
OutperformOutperform
HC Wainwright & Co.2025-10-14
Maintains
BuyBuy
Guggenheim2025-09-08
Maintains
BuyBuy
HC Wainwright & Co.2025-03-24
Maintains
NeutralNeutral
HC Wainwright & Co.2024-12-27
Maintains
NeutralNeutral

Wall Street analysts have recently issued updated ratings on Assembly Biosciences, Inc. (ASMB) stock. Of the recent 30 rating actions, 2 were upgrades and 5 were downgrades. 11 analysts currently cover ASMB.

Analyst Recommendation Trends

Buy ratings12↑ +1
Hold ratings00
Sell ratings00

ASMB analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$58M

↓ 11.5% YoY

Revenue Next Year

$43M

↓ 25.8% YoY

EPS This Year

$-1.68

EPS Next Year

$-3.13

↑ 86.3% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ASMB EPS of $-1.68 for the current fiscal year, based on estimates from 2 analysts. The ASMB revenue forecast is $58M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ASMB stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ASMB price target is $37.67 (+67.0% upside), with an analyst consensus of Buy.

The ASMB short-term stock prediction for tomorrow is $21.43 (-5.00%). The ASMB stock price prediction for 2027 estimates an average of $29. The ASMB stock prediction for 2030 projects a range of $36–$42.

Assembly Biosciences, Inc. trades on NASDAQ under the ticker ASMB. The ASMB stock outlook for 2027 is broadly positive, supported by a Buy consensus among 55% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ASMB forecast · 8 questions

According to 11 Wall Street analysts, the average 12-month ASMB price target is $37.67, with a high forecast of $40.00 and a low of $35.00. The median price target is shown in the chart above when available. This implies +67.0% potential upside from the current price of $22.56.

ASMB price targetWhat is ASMB price targetASMB analyst price targetASMB 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.